Immunome, Inc. (IMNM)
NASDAQ: IMNM · Real-Time Price · USD
25.82
+0.30 (1.18%)
Aug 6, 2026, 4:00 PM EDT - Market closed
Immunome Revenue
Immunome had revenue of $4.01M in the twelve months ending March 31, 2026, down -63.29% year-over-year. In the year 2025, Immunome had annual revenue of $6.94M, down -23.23%.
Revenue (ttm)
$4.01M
Revenue Growth
-63.29%
P/S Ratio
728.30
Revenue / Employee
$19,490
Employees
206
Market Cap
2.92B
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 6.94M | -2.10M | -23.23% |
| Dec 31, 2024 | 9.04M | -4.98M | -35.50% |
| Dec 31, 2023 | 14.02M | - | - |
| Dec 31, 2022 | - | - | - |
| Dec 31, 2021 | - | - | - |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Related Stocks
| Company Name | Revenue |
|---|---|
| Tarsus Pharmaceuticals | 535.08M |
| Beam Therapeutics | 156.04M |
| Nurix Therapeutics | 36.77M |
| uniQure | 18.67M |
| NewAmsterdam Pharma Company | 7.12M |
| AtaiBeckley | 3.49M |
| Celldex Therapeutics | 865.00K |
IMNM News
- 13 hours ago - Immunome Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - Business Wire
- 17 days ago - Immunome announces first patient dosed in Phase 1 IM-3050 trial - TheFly
- 17 days ago - Immunome Announces First Patient Dosed in Phase 1 Trial Evaluating IM-3050, an FAP-Targeted Radioligand Therapy, in Patients with FAP-Expressing Advanced Solid Tumors - Business Wire
- 4 weeks ago - Immunome’s NDA for varegacestat in desmoid tumors accepted by FDA - TheFly
- 4 weeks ago - Immunome Announces U.S. FDA Acceptance of New Drug Application for Varegacestat for the Treatment of Adults with Desmoid Tumors - Business Wire
- 2 months ago - Immunome announces first patient dosed in Phase 1 trial of IM-1617 - TheFly
- 2 months ago - Immunome Announces First Patient Dosed in Phase 1 Trial Evaluating IM-1617, a Potential First-in-Class ADC, in Patients with Advanced Solid Tumors - Business Wire
- 2 months ago - Immunome Transcript: AGM 2026 - Transcripts